ClinicalTrials.gg
CompletedNCT00066092Updated Feb 28, 2008

Pegfilgrastim PBPC Mobilization Study

A Phase 2 interventional study of pegfilgrastim 12 mg and filgrastim in Lymphoma, Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-28.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pegfilgrastim in Lymphoma — none open to participants now, 1 under way, none of them phase 3. pegfilgrastim · Lymphoma.

Enrollment
7th of 13
41 · median 41
Started
2003
the only one that year
Phase 2
8 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
1 of 13
Amgen

Among the 13 studies testing pegfilgrastim in Lymphoma, this one is the 7th largest by enrollment, is the only one that started in 2003, is one of 8 in phase 2, and was the 3rd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 13 studies testing pegfilgrastim in Lymphoma is open now. The open studies under Lymphoma, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing pegfilgrastim in Lymphoma as a file.
02

Study summary

This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

Read the detailed description

This is a research study for Hodgkin's Disease and Non-Hodgkin's Lymphoma (NHL) patients who will receive high-dose chemotherapy with autologous peripheral blood stem cell (PBSC or PBPC) transplant. The chemotherapy doses are high enough to severely suppress the bone marrow (where blood cells are made) and cause very low blood counts. A collection of stem cells (very young blood cells) followed by reinfusion to restore blood counts will be done to stimulate recovery of your blood counts. This procedure is called leukapheresis. Giving growth factors to patients is a method to increase the number of PBPC that can be collected during leukapheresis. This process of giving growth factors to patients is called mobilization (moving cells from the bone marrow to the peripheral blood where they can be collected). The purpose of this study is to determine if pegfilgrastim, an investigational drug, can safely and effectively mobilize stem cells. Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization. Pegfilgrastim is a modified version of Filgrastim that is longer acting.

03

Conditions studied

  • Lymphoma
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Hematology
  • Oncology

Keywords

  • PBPC transplant
  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma
  • NHL
  • mobilization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Hodgkin's or non-Hodgkin's lymphoma patients suitable for an autologous PBPC transplant - No previous bone marrow or PBPC transplant
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Pegfilgrastim 6 mg

    Pegfilgrastim 6 mg given once for PBPC mobilization

    Drug: pegfilgrastim 6 mg

  • Experimental
    Pegfilgrastim 12 mg

    Pegfilgrastim 12 mg given once for PBPC mobilization

    Drug: pegfilgrastim 12 mg

  • Active comparator
    filgrastim

    Filgrastim given daily for PBPC mobilization

    Drug: filgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. CD34+ collection during the collection phase

    Time frame: 10 days

Secondary outcomes

  1. Time to ANC and platelet engraftment post-transplant

    Time frame: 100 days

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Mar 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2003
First posted
Aug 5, 2003
Start
Apr 2003
Primary completionActual
Mar 2004
CompletionActual
Oct 2004
Last update
Feb 28, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00066092
Lead sponsor
Amgen
First posted
Aug 5, 2003
Start date
Apr 2003
Primary completion
Mar 2004
Completion
Oct 2004
Last update
Feb 28, 2008

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion